Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $30
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $29 to $30.
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $29 to $30.